Targeted Therapies for EGFR Exon 20 Insertion Mutation in Non-Small-Cell Lung Cancer.

Int J Mol Sci · 2024 · PMC11172945 · PMID 38892105

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

Median OS displayed a favorable trend for the combination arm, with a survival rate of 24.4 months in the chemotherapy group and no median reached in the amivantamab group.

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.